Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP860363.RAypa77h26BwAKGLwSk_dpH2c_cZc-Q0_NCGOQSqfgh0s130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP860363.RAypa77h26BwAKGLwSk_dpH2c_cZc-Q0_NCGOQSqfgh0s130_assertion type Assertion NP860363.RAypa77h26BwAKGLwSk_dpH2c_cZc-Q0_NCGOQSqfgh0s130_head.
- NP860363.RAypa77h26BwAKGLwSk_dpH2c_cZc-Q0_NCGOQSqfgh0s130_assertion description "[Furthermore, the use of the FDA-approved drug trifluoperazine hydrochloride (TFP), which has been shown to inhibit FOXO1 nuclear export, restored sensitivity to AKT-driven erlotinib resistance through modulation of the KLF6/FOXO1 signaling cascade in both cell culture and xenograft models of lung adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP860363.RAypa77h26BwAKGLwSk_dpH2c_cZc-Q0_NCGOQSqfgh0s130_provenance.
- NP860363.RAypa77h26BwAKGLwSk_dpH2c_cZc-Q0_NCGOQSqfgh0s130_assertion evidence source_evidence_literature NP860363.RAypa77h26BwAKGLwSk_dpH2c_cZc-Q0_NCGOQSqfgh0s130_provenance.
- NP860363.RAypa77h26BwAKGLwSk_dpH2c_cZc-Q0_NCGOQSqfgh0s130_assertion SIO_000772 22653055 NP860363.RAypa77h26BwAKGLwSk_dpH2c_cZc-Q0_NCGOQSqfgh0s130_provenance.
- NP860363.RAypa77h26BwAKGLwSk_dpH2c_cZc-Q0_NCGOQSqfgh0s130_assertion wasDerivedFrom befree-20140225 NP860363.RAypa77h26BwAKGLwSk_dpH2c_cZc-Q0_NCGOQSqfgh0s130_provenance.
- NP860363.RAypa77h26BwAKGLwSk_dpH2c_cZc-Q0_NCGOQSqfgh0s130_assertion wasGeneratedBy ECO_0000203 NP860363.RAypa77h26BwAKGLwSk_dpH2c_cZc-Q0_NCGOQSqfgh0s130_provenance.